New Mechanism Findings Offer Insights Into Phase 2 Signal
Filed with ASX ·
6ix is reading this filing.
Argenica Therapeutics Ltd on 6ix
Earlier from Argenica Therapeutics
- Appendix 4E & Annual Report to 30 June 2026
- ARG007 Shows Significant Neuroprotection in Concussion Study
- ARG007 (Xaranetide) Completes All Three FDA Requested Assays
- WHO Confirms Xaranetide as INN for ARG-007
- IND Application Advanced With Successful Completion of Assay
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics